Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
March 14 2023 - 6:21PM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immuno-oncology company developing novel T cell engagers, today
announced that it will present data from five preclinical
investigations in poster presentations at the American Association
for Cancer Research (AACR) Annual Meeting being held in Orlando,
Fla., April 14-19, 2023.
“The breadth of data from Harpoon’s five poster presentations at
AACR supports further investigation of additional tumor targets,
combination approaches with TriTACs®, as well as our
next-generation technology platform with conditionally active T
cell engager prodrugs, or ProTriTACs™,” said Julie Eastland,
President and Chief Executive Officer of Harpoon Therapeutics.
“Additionally, the preclinical data investigating the activity of
TriTAC in an immunocompetent mouse model provide further validation
of our ongoing and planned clinical efforts with HPN328 and HPN217,
leveraging our proprietary TriTAC T cell engager platform. We look
forward to further validation in the clinic as our research efforts
continue.”
Details of the AACR poster presentations are as follows:
Title: Long-term anti-tumor immunity
induced by HPN328, a DLL3-targeting tri-specific, half-life
extended T cell engager, in a preclinical immunocompetent mouse
modelAbstract Number:
4131Session: Immunology/Determinants of
Immunotherapeutic EffectivenessSession Date, Time:
Tuesday, April 18, 9 a.m. - 12:30 p.m. ETLocation:
Poster Section 24
Title: Anti-tumor activity of HPN328, a
DLL3-targeting tri-specific, half-life extended T cell engager, is
enhanced by combining with an anti-PD-L1 antibody in an
immunocompetent mouse modelAbstract Number:
5070Session: Immunology/Combination
Immunotherapies 1Session Date, Time: Tuesday April
18, 1:30 - 5 p.m. ETLocation: Poster Section
21
Title: Anti-tumor activity of HPN217, a
BCMA-targeting tri-specific T cell engager, is enhanced by
γ-secretase inhibitors in preclinical modelsAbstract
Number: 5081Session:
Immunology/Combination Immunotherapies
1 Session
Date, Time: Tuesday April 18, 1:30 - 5 p.m.
ETLocation: Poster Section 21
Title: TROP2 ProTriTAC™, a
protease-activated T cell engager prodrug targeting TROP2 for the
treatment of solid tumorsAbstract Number:
2928Session: Immunology/Therapeutic Antibodies
2Session Date, Time: Monday April 17, 1:30 - 5
p.m. ETLocation: Poster Section 23
Title: ITGB6 ProTriTAC™, a
protease-activated T cell engager prodrug targeting Integrin-β6 for
the treatment of solid tumorsAbstract Number:
2927Session: Immunology/Therapeutic Antibodies
2Session Date, Time: Monday April 17, 1:30 - 5
p.m. ETLocation: Poster Section 23
The posters will also be available on Harpoon’s website
following the presentations.
For more details about the AACR Annual Meeting, please visit:
https://www.aacr.org/meeting/aacr-annual-meeting-2023/
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immuno-oncology
company developing a novel class of T cell engagers that harness
the power of the body’s immune system to treat patients suffering
from cancer and other diseases. T cell engagers are engineered
proteins that direct a patient’s own T cells to kill target cells
that express specific proteins, or antigens, carried by the target
cells. Using its proprietary Tri-specific T cell Activating
Construct (TriTAC®) platform, Harpoon is developing a pipeline of
novel TriTACs initially focused on the treatment of solid
tumors and hematologic malignancies. Harpoon has also developed a
proprietary ProTriTAC™ platform, which applies a prodrug
concept to its TriTAC platform to create a therapeutic T cell
engager that remains inactive until it reaches the tumor. Harpoon’s
third proprietary technology platform, extended release TriTAC-XR,
is designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “look forward,” “may,” “suggest,” “expect,”
“potential,” “continued,” “further,” “will,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking
statements are based on Harpoon Therapeutics’ expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties that
could cause Harpoon Therapeutics’ clinical development programs,
future results or performance to differ significantly from those
expressed or implied by the forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the expected progress,
results, and plans pertaining to Harpoon Therapeutics’ clinical
trials and other statements that are not historical fact. Many
factors may cause differences between current expectations and
actual results, including unexpected safety or efficacy data
observed during clinical studies, preliminary data and trends may
not be predictive of future data or results, may not
demonstrate safety or efficacy or lead to regulatory approval by
the FDA or other regulatory agencies, clinical trial site
activation or enrollment rates that are lower than expected,
changes in expected or existing competition, changes in the
regulatory environment, the uncertainties and timing of the
regulatory approval process, the timing and results of unexpected
litigation or other disputes, and the sufficiency of Harpoon
Therapeutics’ cash resources. These and other factors that may
cause Harpoon Therapeutics’ actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Harpoon Therapeutics’ filings with
the U.S. Securities and Exchange Commission, including under
“Risk Factors” in Harpoon Therapeutics’ quarterly report on Form
10-Q for the quarter ended September 30, 2022, and future
filings by Harpoon Therapeutics. Except as required by
law, Harpoon Therapeutics assumes no obligation to update
any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes
available.
Contacts:
Investors:ICR WestwickeRobert H. UhlManaging
Director858-356-5932 robert.uhl@westwicke.com
Media:Uncapped CommunicationsKerry
Walton303-588-0599kerry.walton@uncappedcommunications.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Sep 2023 to Sep 2024